The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|March 14, 2011
Advances in Kidney Cancer Over the Past Several Years
Author(s)Ana M. Molina, MD
Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Explains Advancements in Kidney Cancer Over the Past Several Years
Advertisement
Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Explains Advancements in Kidney Cancer Over the Past Several Years
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5